MedTrace Logo

Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer

NCT01721785 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 307

Last updated 2017-03-22

No results posted yet for this study

Summary

The purpose of this study is to determine the clinical value of the novel MRI-techniques DWI and gadofosveset-enhanced MRI for the management of rectal cancer patients.

Conditions

  • Rectal Neoplasms
  • Magnetic Resonance Imaging
  • Neoplasms Staging

Interventions

DRUG

GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]

Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Regina Beets-Tan, Prof. MD. · Radiology, MUMC

  • Geerard Beets, Ass Prof. MD · Surgery, MUMC

  • Doenja Lambregts, MD · Radiology, MUMC

  • Monique Maas, MD · Radiology, MUMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01721785 on ClinicalTrials.gov